A detailed history of Roberts Glore & CO Inc transactions in Incyte Corp stock. As of the latest transaction made, Roberts Glore & CO Inc holds 6,300 shares of INCY stock, worth $475,335. This represents 0.12% of its overall portfolio holdings.

Number of Shares
6,300
Previous 8,285 23.96%
Holding current value
$475,335
Previous $502,000 17.13%
% of portfolio
0.12%
Previous 0.15%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$57.33 - $68.61 $113,800 - $136,190
-1,985 Reduced 23.96%
6,300 $416,000
Q2 2024

Aug 14, 2024

BUY
$51.18 - $63.75 $5,373 - $6,693
105 Added 1.28%
8,285 $502,000
Q4 2023

Feb 12, 2024

SELL
$52.16 - $64.19 $171,345 - $210,864
-3,285 Reduced 28.65%
8,180 $513,000
Q3 2023

Nov 13, 2023

BUY
$57.77 - $65.93 $9,532 - $10,878
165 Added 1.46%
11,465 $662,000
Q2 2023

Aug 14, 2023

BUY
$60.95 - $75.51 $68,568 - $84,948
1,125 Added 11.06%
11,300 $703,000
Q1 2023

May 08, 2023

SELL
$70.23 - $86.01 $10,534 - $12,901
-150 Reduced 1.45%
10,175 $735,000
Q4 2022

Feb 13, 2023

SELL
$67.18 - $84.11 $16,795 - $21,027
-250 Reduced 2.36%
10,325 $829,000
Q4 2021

Feb 11, 2022

BUY
$63.34 - $74.11 $331,901 - $388,336
5,240 Added 98.22%
10,575 $776,000
Q3 2021

Nov 12, 2021

BUY
$68.67 - $84.02 $10,300 - $12,603
150 Added 2.89%
5,335 $367,000
Q1 2021

May 06, 2021

BUY
$76.02 - $100.5 $178,647 - $236,175
2,350 Added 82.89%
5,185 $421,000
Q4 2020

Feb 09, 2021

BUY
$80.74 - $97.7 $24,222 - $29,310
300 Added 11.83%
2,835 $246,000
Q2 2020

Aug 13, 2020

BUY
$74.18 - $108.93 $188,046 - $276,137
2,535 New
2,535 $263,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Roberts Glore & CO Inc Portfolio

Follow Roberts Glore & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Roberts Glore & CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Roberts Glore & CO Inc with notifications on news.